Long-acting GLP-1RA reduces blood sugar by stimulating and activating GLP-1R for a prolonged period, promoting the secretion of insulin and inhibiting the secretion of glucagon, and it has a limited effect on postprandial blood sugar fluctuations
22,23 While DECLARE-TIMI 58 did not demonstrate superiority of dapagliflozin over placebo for MACE, it did show a reduction in heart-failure hospitalization similar to that seen with empagliflozin or canagliflozin
During this time comprehensive input was collected via face to face and teleconference meetings, and 103 formal submissions received, representing a wide range of stakeholder views
Well design the safest, most effective combination for your goals
Then, the dose is increased every month or so, going up to 0.5 mg, then 1 mg, then 1.7 mg
Conversely, those starting at the lowest available dose typically progress through side effects more rapidly